A Trial of Tisotumab Vedotin in Cervical Cancer

A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer

A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.

Study Overview

• Status: Completed
• Conditions: Cervical Cancer
• Intervention / Treatment: Drug: tisotumab vedotin

Detailed Description

The purpose of the trial is to evaluate the efficacy and safety/tolerability of tisotumab vedotin in patients with previously treated, recurrent or metastatic cervical cancer. Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), a protein aberrantly expressed in a wide number of tumors including cervical cancer. Preliminary safety and efficacy data observed in a cohort of previously treated cervical cancer patients suggest a positive benefit risk profile for this population of high unmet need.

• Study Type: Interventional
• Enrollment (Actual): 102
• Phase: Phase 2

Contacts and Locations

Study Locations

• Belgium
  • Brugge, Belgium, 8000
    • AZ Sint-Jan Brugge-Oostende AV
  • Brussels, Belgium, 1200
    • Cliniques Universitaires Saint-luc
  • Charleroi, Belgium, 6000
    • Grand Hôpital de Charleroi
  • Gent, Belgium, 9000
    • Universitair Ziekenhuis Gent
  • Gent, Belgium, 9000
    • Algemeen Ziekenhuis Maria MiddelaresMedical Oncology - IKG
  • Leuven, Belgium, 3000
    • UZLeuvenGynaecologische oncologie
  • Libramont, Belgium, 6800
    • Centre Hospitalier de l'Ardenne
  • Liege, Belgium, 4000
    • CHU de LIEGE/ Oncologie Médicale, domaine universitaire du Sart Tilman
  • Liège, Belgium, 4000
    • CHC SAINT Montlegia
  • Namur, Belgium, 5000
    • CHU UCL Namur site de Sainte Elisabeth
• Czechia
  • Brno, Czechia, 62500
    • Fakultni nemocnice Brno
  • Olomouc, Czechia, 77900
    • Fakultni nemocnice Olomouc Onkologic
  • Prague, Czechia, 12851
    • Vseobecna Fakultni Nemocnice V Praze
  • Prague, Czechia, 18081
    • Nemocnice Na Bulovce, Gynekologicko-porodnicka kl
• Denmark
  • Aalborg, Denmark, 9000
    • Aalborg Universitetshospital
  • Copenhagen, Denmark, 2100
    • Rigshospitalet
• Germany
  • Duesseldorf, Germany, 45147
    • Kliniken Essen-Mitte
  • Hamburg, Germany, 20246
    • Universitaetsklinikum Hamburg-Eppendorf
  • Münich, Germany, 81377
    • Klinikum der Universität München
• Italy
  • Bologna, Italy, 40138
    • Policlinico S.Orsola-Malpighi, SSD Oncologia Medica Addarii
  • Meldola, Italy
    • Irst Irccs
  • Milan, Italy, 20133
    • Fondazione IRCCS Istituto Nazionale dei Tumori
  • Naples, Italy, 80131
    • Istituto Nazionale Tumori Fondazione G. Pascale
  • Rome, Italy, 00168
    • Policlinico Universitario Agostino Gemelli, UOC Patologia Ostetrica e Ginecologica
• Spain
  • A Coruna, Spain, 15006
    • Hospital Teresa Herrera-Chuac
  • Barcelona, Spain, 08036
    • Hospital Clinic Barcelona
  • Hospitalet de Llobregat, Spain, 08908
    • Hospital Duran I Reynals ICO Hospitalet
  • Madrid, Spain, 28040
    • Hospital Clinico San Carlos
  • Madrid, Spain, 28041
    • Hospital Universitario 12 de Octubre
  • Madrid, Spain, 28027
    • Clínica Universidad de Navarra (Sede Madrid)
  • Madrid, Spain, 28046
    • Hospital Universitario La Paz, Edificio dotacional de Oncología
  • Palma de Mallorca, Spain, 07198
    • Fundacion Hospital Son Llatzer
• Sweden
  • Lund, Sweden, 22185
    • Skåne University Hospital
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • University of Alabama
  • Arizona
    • Phoenix, Arizona, United States, 85016
      • Arizona Oncology Associate - Biltmore Cancer Center
  • California
    • Los Angeles, California, United States, 90095
      • UCLA Dept. of OBGYN
  • Florida
    • Jacksonville, Florida, United States, 32258
      • Southern Baptist Hospital of Florida, Inc
    • Miami, Florida, United States, 33136
      • University of Miami Miller School of Medicine
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • University of Gynecologic Oncology
  • Indiana
    • Indianapolis, Indiana, United States, 46219
      • Community Hospital East
  • Kentucky
    • Louisville, Kentucky, United States, 40207
      • Louisville Oncology
  • Massachusetts
    • Springfield, Massachusetts, United States, 01105
      • Baystate Medical Center
  • Nevada
    • Las Vegas, Nevada, United States, 89169
      • Women's Cancer Center of Nevada
  • New Jersey
    • Camden, New Jersey, United States, 08103
      • MD Anderson Cancer Center at Cooper University Hospital
  • New Mexico
    • Albuquerque, New Mexico, United States, 87102
      • University of New Mexico Comprehensive Cancer Center (UNMCCC)
  • Ohio
    • Cincinnati, Ohio, United States, 45267
      • University of Cincinnati
    • Hilliard, Ohio, United States, 43210
      • The Ohio State University Wexner Medical Center
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73104
      • Stephenson Cancer Center
    • Tulsa, Oklahoma, United States, 74146
      • Oklahoma Cancer Specialists and Research Institute, LLC
  • Pennsylvania
    • Willow Grove, Pennsylvania, United States, 19090
      • Abington Memorial Hospital
  • South Carolina
    • Greenville, South Carolina, United States, 29607
      • Bon Secours Saint Francis Cancer Center
  • Texas
    • Houston, Texas, United States, 77030
      • UT Health McGovern Medical School
  • Wisconsin
    • Milwaukee, Wisconsin, United States, 53226
      • Froedtert & Medical College Clinics

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria

• Patients with extra-pelvic metastatic or recurrent cervical cancer including squamous cell, adenocarcinoma or adenosquamous histology who have experienced disease progressed on standard of care chemotherapy in combination with bevacizumab, if eligible.
• Measurable disease according to RECIST v1.1 as assessed by IRC.
• Age ≥ 18 years.
• Acceptable renal function
• Acceptable liver function
• Acceptable hematological status
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• A negative serum pregnancy test for patients of reproductive potential.
• All patients must provide a fresh or archival biopsy during screening.
• Following receipt of verbal and written information about the trial, patients must provide signed informed consent before any trial-related activity is carried out.

Exclusion Criteria

• Have received no more than 2 prior systemic treatment regimens for recurrent or metastatic cervical cancer.
• Known past or current coagulation defects leading to an increased risk of bleeding;
• Ongoing major bleeding
• Active ocular surface disease
• Known past or current malignancy other than the inclusion diagnosis.
• Peripheral neuropathy grade ≥ 2

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single arm; tisotumab vedotin (IV), 2.0 mg/kg, every 3 weeks (1Q3W)	Drug: tisotumab vedotin; All patients will be treated with tisotumab vedotin once every three weeks until progression or toxicity; Other Names: TIVDAK

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC)	The confirmed OR is defined as best overall response of confirmed complete response (CR) or confirmed partial response (PR) based upon RECIST v1.1, assessed by the IRC. The CR is disappearance of all target and non-target lesions and no new lesions. A confirmed CR is 2 CRs (CR-CR sequence) that were separated by at least 4 weeks with no evidence of progression in-between. The PR is ≥ 30% decrease in the sum of diameters of target lesions (compared to baseline) and no unequivocal progression of existing non-target lesions and no new lesion. A confirmed PR is PR-PR sequence or PR-CR sequence that were separated by at least 4 weeks. The intermediate missing (Not Evaluable [NE]) scan evaluations between response scan and confirmation scan were allowed, eg, PR-NE-PR and PR-NE-NE-PR was considered PR confirmed (a repeat scan not earlier than 4 weeks after initial scan documenting response). 95% CI was calculated using the Clopper-Pearson method.	From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Plasma Concentrations of Tisotumab Vedotin (HuMax-TF), Tisotumab Vedotin Antibody-drug Conjugate (HuMax-TF-ADC), and Free Monomethyl Auristatin E (MMAE)	Plasma concentrations of HuMax-TF, HuMax-TF-ADC, and Free MMAE measures on Cycle 1 Day 1 (predose and end of infusion) and Cycle 6 Day 1 (predose and end of infusion) are reported.	Predose and end of infusion of Cycle 1 Day 1 (C1D1) and Cycle 6 Day 1 (C6D1)
Duration of Response (DOR) as Assessed by the IRC	The DOR is defined as the duration from the first documented response of CR or PR (the start date of response, not the date when response was confirmed) to the date of the first documented progression disease (PD) verified by IRC or death. Based upon RECIST v1.1, the CR is defined as disappearance of all target and non-target lesions and no new lesions; the PR is defined as ≥ 30% decrease in the sum of diameters of target lesions (compared to baseline) and no unequivocal progression of existing non-target lesions and no new lesion; and the PD is defined as at least 20% increase in the sum of diameters of target lesions (compared to baseline), unequivocal progression of existing non-target lesions, and/or new lesion. The DOR was estimated using Kaplan-Meier method.	From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 49 months)
Percentage of Participants With Confirmed OR as Assessed by the Investigator	The confirmed OR is defined as best overall response of confirmed CR or confirmed PR based upon RECIST v1.1, assessed by the investigator. The CR is defined as disappearance of all target and non-target lesions and no new lesions. A confirmed CR is defined as 2 CRs (CR-CR sequence) that were separated by at least 4 weeks with no evidence of progression in-between. The PR is defined as ≥ 30% decrease in the sum of diameters of target lesions (compared to baseline) and no unequivocal progression of existing non-target lesions and no new lesion. A confirmed PR is defined as PR-PR sequence or PR-CR sequence that were separated by at least 4 weeks. The intermediate missing (NE) scan evaluations between the response scan and the confirmation scan were allowed, eg, PR-NE-PR and PR-NE-NE-PR was considered PR confirmed (a repeat scan not earlier than 4 weeks after initial scan documenting response). 95% CI was calculated using the Clopper-Pearson method.	From Day 1 through investigator verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 49 months)
DOR as Assessed by the Investigator	The DOR is defined as the duration from the first documented response of CR or PR (the start date of response, not the date when response was confirmed) to the date of the first documented PD verified by investigator or death. Based upon RECIST v1.1, the CR is defined as disappearance of all target and non-target lesions and no new lesions; the PR is defined as ≥ 30% decrease in the sum of diameters of target lesions (compared to baseline) and no unequivocal progression of existing non-target lesions and no new lesion; and the PD is defined as at least 20% increase in the sum of diameters of target lesions (compared to baseline), unequivocal progression of existing non-target lesions, and/or new lesion. The DOR was estimated using Kaplan-Meier method.	From Day 1 through investigator verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 49 months)
Time to Response (TTR) as Assessed by the IRC	The TTR is defined as the duration from the start of study drug to the first documented response of either CR or PR based on RECIST v1.1, assessed by the IRC. A confirmed CR is defined as 2 CRs (disappearance of all target and non-target lesions and no new lesions) that were separated by at least 4 weeks with no evidence of progression in-between. A confirmed PR is defined as 2 PRs (≥ 30% decrease in the sum of diameters of target lesions compared to baseline and no unequivocal progression of existing non-target lesions and no new lesion) or an un-confirmed PR and an un-confirmed CR or achieved PR-NE-PR or PR-NE-NE-PR that were separated by at least 4 weeks with no evidence of progression in-between.	From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 49 months)
TTR as Assessed by the Investigator	The TTR is defined as the duration from the start of study drug to the first documented response of either CR or PR based on RECIST v1.1, assessed by the investigator. A confirmed CR is defined as 2 CRs (disappearance of all target and non-target lesions and no new lesions) that were separated by at least 4 weeks with no evidence of progression in-between. A confirmed PR is defined as 2 PRs (≥ 30% decrease in the sum of diameters of target lesions compared to baseline and no unequivocal progression of existing non-target lesions and no new lesion) or an un-confirmed PR and an un-confirmed CR or achieved PR-NE-PR or PR-NE-NE-PR that were separated by at least 4 weeks with no evidence of progression in-between.	From Day 1 through investigator verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 49 months)
Progression Free Survival (PFS) as Assessed by the IRC	The PFS is defined as the time from the start of study drug until the first documentation of PD based on RECIST v1.1, as assessed by the IRC or death due to any cause, whichever occurred first. The PD based upon RECIST v1.1 is defined as at least 20% increase in the sum of diameters of target lesions (compared to baseline), unequivocal progression of existing non-target lesions, and/or new lesion. The PFS was estimated using Kaplan-Meier method.	From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 49 months)
PFS as Assessed by the Investigator	The PFS is defined as the time from the start of study drug until the first documentation of PD based on RECIST v1.1, as assessed by the investigator or death due to any cause, whichever occurred first. The PD based upon RECIST v1.1 is defined as at least 20% increase in the sum of diameters of target lesions (compared to baseline), unequivocal progression of existing non-target lesions, and/or new lesion. The PFS was estimated using Kaplan-Meier method.	From Day 1 through investigator verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 49 months)
Overall Survival (OS)	The OS is defined as the time from the start of study treatment until death due to any cause. The OS was estimated using Kaplan-Meier method.	From Day 1 until death or withdrawal from the study, whichever occurred first (approximately 49 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)	An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE is defined as an AE that meets one of the following criteria: fatal or life-threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; medically significant (an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above [medical and scientific judgment must be exercised in deciding whether an AE is "medically important"]); required inpatient hospitalization or prolongation of existing hospitalization. A TEAE is defined as an AE occurring or worsening between the first dose of tisotumab vedotin and 30 days after the last dose received.	From Day 1 through 30 days after the last dose of study drug (approximately 49 months)
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as TEAEs	Laboratory abnormalities that induced clinical signs or symptoms, required concomitant therapy or required changes during treatment emergent period were reported as TEAEs. Number of participants with abnormal clinical laboratory parameters reported as TEAEs are reported.	From Day 1 through 30 days after the last dose of study drug (approximately 49 months)
Number of Participants With Positive Anti-drug Antibodies (ADA) to Tisotumab Vedotin	Number of participants with positive ADA titer to tisotumab vedotin at baseline and post-baseline are reported. Baseline is defined as the latest available measurement made before the first dose of tisotumab vedotin. For post-baseline results, a participant was considered ADA positive if either ADA is negative at baseline and at least one post-baseline result is positive or positive at baseline and at least one positive post-baseline result with a titer higher than baseline.	Predose of each treatment cycle (Cycle 1 to 21) and end of treatment visit (approximately 49 months)

Collaborators and Investigators

• Sponsor: Seagen Inc.
• Collaborators: Gynecologic Oncology Group; European Network of Gynaecological Oncological Trial Groups (ENGOT); Genmab; Belgian Gynaecological Oncology Group

Publications and helpful links

General Publications

• Coleman RL, Lorusso D, Gennigens C, Gonzalez-Martin A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindelov SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I; innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 May;22(5):609-619. doi: 10.1016/S1470-2045(21)00056-5. Epub 2021 Apr 9.

Study record dates

Study Major Dates

• Study Start (Actual): June 12, 2018
• Primary Completion (Actual): February 6, 2020
• Study Completion (Actual): August 2, 2022

Study Registration Dates

• First Submitted: February 8, 2018
• First Submitted That Met QC Criteria: February 16, 2018
• First Posted (Actual): February 19, 2018

Study Record Updates

• Last Update Posted (Actual): July 25, 2023
• Last Update Submitted That Met QC Criteria: July 11, 2023
• Last Verified: July 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Uterine Cervical Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Tisotumab vedotin
• Other Study ID Numbers: GCT1015-04; innovaTV 204 (Other Identifier: Genmab)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No